InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.08
(
-0.06%
)
Bitcoin
66,359.06
(
-0.42%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119848
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 09/13/2006 4:23:02 PM

Wednesday, September 13, 2006 4:23:02 PM

Post# of 19309
Here’s an indication where it may be beneficial
to give both antithrombin and intermittent heparin:

Use of a Novel Anticoagulation Strategy During ECMO in a Pediatric Population: Single-Center Experience

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
ASAIO J. 2006 September/October;52(5):513-516.

Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C.

Cardiac Surgery Unit and Intensive Care Unit, "San Vincenzo" Hospital, Taormina, Italy; Perfusion Service EPS, Taormina, Italy; Tecno Health, Novara, Italy; Departments of Pediatrics, Surgery, and Bioengineering, Penn State College of Medicine, Hershey, Pennsylvania.

We describe a novel anticoagulation strategy with continuous intravenous antithrombin infusion and intermittent heparin infusion in pediatric population during extracorporeal membrane oxygenation (ECMO).

From November 2004 through February 2006, 11 patients required ECMO for postcardiotomy cardiorespiratory failure. The mean duration of support time was 112 hours (range 68-192 hours).

Since April 2005, we modified our anticoagulation protocol in the last six patients. Continuous antithrombin infusion was started immediately after surgery based on the lab result. The antithrombin level was maintained >100% using the following formula:100 (target value) - (Antithrombin value on lab test) x weight in 4 hours.

Antithrombin value was checked at 4-hour intervals. Heparin infusion was started when the antithrombin value was > 100% and remained stable for more than 12 hours and the amount of bleeding was < 2 ml/kg for more than 3 consecutive hours; then heparin infusion was started at 2 UI/kg/h via the oxygenator (target ACT was not < 150 seconds).

Three patients in the first group died. Eight patients were weaned and discharged; the third, fourth, and fifth required surgical revision for bleeding. One experienced minor neurologic sequelae.

Neither surgical revision nor thromboembolic complications occurred in the new anticoagulation group. A novel anticoagulation strategy utilizing continuous intravenous antithrombin and intermittent heparin infusion reduced significantly surgical revision for bleeding in the first 48 hours. This has translated into excellent overall outcomes.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up